Bio-Techne Corp (TECH)
Solvency ratios
| Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.33 | 1.31 | 1.28 | 1.28 | 1.36 | 1.35 | 1.39 | 1.38 | 1.34 | 1.38 | 1.29 | 1.34 | 1.35 | 1.34 | 1.35 | 1.38 | 1.44 | 1.35 | 1.35 | 1.43 |
The analysis of Bio-Techne Corp’s solvency ratios over the period from September 2020 through June 2025 indicates a consistent absence of leverage through debt. The Debt-to-Assets, Debt-to-Capital, and Debt-to-Equity ratios are uniformly reported as zero throughout all observed periods, suggesting the company has not utilized debt financing during this timeframe. This constitutes a significant indication of a debt-free capital structure, emphasizing reliance on equity or internally generated funds for financing activities.
In terms of financial leverage, the ratio fluctuates narrowly within a narrow range, predominantly between 1.28 and 1.44. The ratios show moderate variation but remain relatively stable, indicating that, despite the lack of debt, the company's use of leverage—possibly via other financial instruments or off-balance-sheet arrangements—maintains a mild degree of financial structure. A leverage ratio of approximately 1.3 to 1.4 suggests a conservative capital structure, with limited reliance on debt financing and a higher proportion of equity financing.
Overall, Bio-Techne Corp’s solvency ratios reflect a conservative, debt-free financial stance throughout the observed period, with stable leverage ratios indicating prudent capital management and minimal financial risk associated with debt obligations. This pattern aligns with a company predominantly financing its operations through non-debt sources, contributing to a robust solvency profile.
Coverage ratios
| Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | 15.73 | 22.91 | 21.62 | 18.17 | 15.66 | 15.43 | 18.75 | 23.88 | 26.55 | 27.44 | 25.35 | 23.45 | 24.53 | 19.10 | 17.54 | 15.65 | 13.57 | 15.63 | 12.62 | 10.69 |
The interest coverage ratios for Bio-Techne Corp over the specified period exhibit a generally favorable trend, indicating consistent ability to meet interest obligations from operating earnings. Starting at a ratio of 10.69 as of September 30, 2020, the metric increased substantially, reaching 25.35 by December 31, 2022, illustrating an improved capacity to cover interest expenses through earnings before interest and taxes (EBIT). The peak occurred around March 31, 2022, with a ratio of 27.44, reflecting a strong earnings position relative to interest obligations.
Subsequently, the ratio experienced some fluctuations, declining to 23.88 by September 30, 2023, and further decreasing to 18.75 as of December 31, 2023. This downward movement suggests some reduction in earnings relative to interest expenses during this period. Nevertheless, the interest coverage remains above a conservative threshold of 3.0, indicating that the company maintains sufficient earnings to service its interest costs comfortably.
Projected values indicate some variability in future periods, with ratios of approximately 15.43 as of March 31, 2024, and an eventual rise to 21.62 by December 31, 2024. The ratios for 2025 suggest some stabilization, with estimates around 22.91 in the first quarter and 15.73 in the second quarter, reflecting potential short-term fluctuations but maintaining an overall capacity to cover interest expenses adequately.
Overall, the data indicates that Bio-Techne Corp has historically maintained strong interest coverage ratios, with recent periods still demonstrating a comfortable margin of safety, although some decline has been observed from recent peaks. Continued monitoring of these ratios will be essential to assess future financial stability and the company’s ability to meet its interest obligations under varying financial conditions.